3 results
The study will be conducted in two parts, Part A and Part B. The main purpose of Part A of the study is to evaluate the safety and tolerability, the blood levels and the extent of receptor blockade of CCX872-B in patients with pancreatic cancer. In…
The primary objective is:* To evaluate RBC transfusion independence (RBC-TI) of luspatercept compared with placebo for the treatment of anemia due to IPSS-R very low, low, or intermediate risk MDS in subjects with ring sideroblasts (* 15%) who…
Primary objective:• To evaluate the efficacy of luspatercept on RBC transfusion independence (RBC-TI for 12 weeks [84 days] with an associated concurrent mean hemoglobin increase >= 1.5 g/dL) compared with epoetin alfa for the treatment of…